Intratumoral Cancer Therapies Market Global Scenario, Market Size, Outlook, Trend, and Forecast, 2019 – 2028

OVERVIEW

Cancer is a leading cause of global death, which nearly caused 10 million deaths in 2020. The treatment of cancer typically includes chemotherapy, hormone therapy, immunotherapy, gene therapy, radiotherapy, and targeted therapy. However, in some of the cases, patients do not respond to any of the available treatment options or develop resistance to available therapies. This creates a lacuna, which in turn creates an opportunity for the scientific community to develop a keen interest in Intratumoral Cancer Therapies that are immunotherapies and the immunization is administered directly into tumour’s through injections. By filling this lacuna of cancer treatment, immunotherapy has evolved and had come a long way with its benefits and possesses advantages over conventional cancer treatment methods, which is widely accepted.

MARKET DYNAMICS

According to an estimate, 19,292,789 new cancer cases were diagnosed worldwide with nearly 9,958,133 deaths due to cancers. Additionally, according to estimates from the International Agency for Research on Cancer (IARC), by 2040, the global burden of cancers is expected to continuously grow to 27.5 million new cancer cases and 16.3 million deaths worldwide. This rapid increment in the incidence of cancer cases is predicted to drive the demand for advanced cancer therapies for the effective treatment of patients worldwide. Thus, according to the above-mentioned factors, the cancer therapy as well as intratumoral cancer therapies market is predicted to witness tremendous growth over the forecast period.

REGIONAL INSIGHTS

In contemporary times, North America currently dominates the Cancer Therapy Market and is expected to continue during the forecast period. In the future, North America is expected to acquire more market share in the market due to increased adoption of cancer therapy .According to the report of GLOBOCAN 2020, an estimated 2,281,658 new cancer cases were diagnosed in the United States in 2020, with nearly 612,390 deaths. In USA, the most common cancers were breast (253,465), lung (227,875, colon (101,809) and prostate (209,512) when observed in the year 2020. The statistics of the referred market predict a positive outcome for the upcoming investment in this field.

SEGMENTATION OF INTRATUMORAL CANCER THERAPIES MARKET

There are different categories of Intramoral therapies ranging from cytokines, pathogen-associated molecular patterns (PAMPs), oncolytic viruses, monoclonal antibodies, and small molecules. The present Intratumoral cancer therapy market comprises of three approved therapies:

  • Imlygic (talimogene laherparepvec; T-Vec) approved by FDA(USA) to treat melanoma
  • Hensify (NBTXR3) for the treatment of patients suffering from soft tissue sarcoma
  • Delytact(teserpaturev) for the treatment of malignant glioma

The intratumoral cancer therapies market has registered the highest growth in North America during the past few years and this progressive trend is expected to continue in the forthcoming years as well. This is a result of the growing geriatric population.

LEADING MARKET PLAYERS IN THE INDUSTRY

Some of the key/prominent /major players operating in the Intratumoral Cancer market are Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune, Philogen, Exicure, Sirnaomics, Nanobiotix, Intensity Therapeutics, NanOlogy, Lokon Pharma, Immunicum, DNAtrix, Treovir, Idera Pharmaceuticals, and Immunovative Therapies among others. These companies are working in the contemporary times for the development of Intratumoral cancer therapies at different stages of clinical trials; thereby boosting the competition in the Intratumoral cancer market. The emerging Intratumoral cancer therapies pipeline is majorly curing melanoma, brain cancer, nonmelanoma skin cancer, head, and neck cancer.

SCOPE AND SEGMENTATION OF INTRATUMORAL CANCER THERAPIES MARKET

BASED ON PRODUCT

  • Drugs
    • Opioids
    • Non-steroidal anti-inflammatory drugs (NSAIDs)
    • Anticonvulsants
    • Antidepressants
  • Devices
    • Neurostimulation devices
      • Spinal cord stimulation (SCS) devices
      • Transcutaneous electrical nerve stimulation (TENS) devices
    • Analgesic infusion pumps
    • Ablation devices
      • Radiofrequency ablation devices
      • Cryoablation devices

BASED ON INDICATION

  • Neuropathic Pain
  • Arthritis Pain
  • Chronic Back Pain
  • Cancer Pain
  • Migraine
  • Fibromyalgia

BASED ON APPLICATION

  • Neuropathy
  • Oncology
  • Musculoskeletal

BASED ON DISTRIBUTION CHANNEL

  • Direct
  • Indirect

BASED ON END USER

  • Hospitals
  • Clinics
  • Nursing Homes
  • Research Centres & Universities

GEOGRAPHICAL ANALYSIS

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Netherlands
    • Russia
    • Sweden
    • Switzerland
    • Rest of Europe
  • Asia-Pacific (APAC)
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
  • Middle East & Africa (MEA)
    • Saudi Arabia
    • South Africa

LEADING MARKET PLAYERS OF INTRATUMORAL CANCER THERAPIES MARKET

  • ELI LILLY AND COMPANY
  • GlaxoSmithKnile plc
  • Pfizer Inc.
  • Medtronic plc
  • Abott Laboratories
  • Boston Scientific Corporation
  • Novartis AG
  • Jhonson & Jhonson
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Bectojn,Dickinson and Company
  • Sanofi S.A.
Back to top

Payment Options

Single User $3971.25
$5295
Five User $4646.25
$6195
Enterprise $6149.25
$8199
Datapack $1649.25
$2199
Short Report: $2324.25
$3099